Status:
UNKNOWN
ECCO2R in the Treatment of Acute Exacerbation of COPD With Severe Hypercapnia
Lead Sponsor:
Li Xuyan
Conditions:
Lung Diseases, Obstructive
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Patients with moderate to severe acute exacerbation of chronic obstructive pulmonary disease are often complicated with hypercapnia and respiratory failure, so they need to be admitted to ICU for moni...
Eligibility Criteria
Inclusion
- AECOPD patients.
- The patients with hypercapnia respiratory failure were admitted to ICU and needed noninvasive ventilation.
- The results of blood gas analysis showed pH \<7.30, PaCO2\> 50 mmHg.
- There were high risk factors for failure of noninvasive ventilation: after receiving continuous 2 hours of noninvasive ventilation, the arterial blood pressure showed the pH value was ≤ 7.30, while PaCO2 was 20% higher than the baseline value, and any one or more of the following conditions were combined: respiratory rate ≥ 30 times / min, assisted respiratory muscle breathing; contradictory breathing.
- Informed consents were sighed.
Exclusion
- The mean arterial pressure was less than 60 mmHg after volume and vasoactive drug treatment.
- There were anticoagulant contraindications.
- Weight over 120kg.
- Patients with malignant tumor or other complications, the expected survival time was less than 30 days.
- It could not cooperate with noninvasive ventilation or has contraindication of noninvasive ventilation.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT04842344
Start Date
May 1 2021
End Date
March 31 2024
Last Update
April 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Institute of Respiratory Medicine, Beijing Chao-yang Hospital, Capital Medical University
Beijing, China, 100020